Learn More
Pembrolizumab Mouse, Biotin, Clone: 10E12C6, GenScript™
Description
Reconstitute the lyophilized antibody with deionized water (or equivalent) to a final concentration of 0.5 mg/mL. Pembrolizumab (Keytruda) is a humanized monoclonal antibody that is approved by the U.S. Food and Drug Administration for the treatment of patients with unresectable or metastatic melanoma. Pembrolizumab binds to the human cell surface receptor PD-1 (Programmed Cell Death Protein 1) and blocks its interaction with PD-L1, resulting in the activation of T-cell-mediated immune responses against tumor cells. GenScript Anti-Pembrolizumab Antibody (10E12C6)[BIOTIN], mAb, Mouse is produced from a hybridoma resulting from the fusion of SP2/0 myeloma and B-lymphocytes obtained from a mouse immunized with Pembrolizumab.
Specifications
Specifications
| Antigen | Pembrolizumab |
| Applications | Blocking Assay, ELISA |
| Classification | Monoclonal |
| Clone | 10E12C6 |
| Conjugate | Biotin |
| Formulation | PBS with BSA and 0.02% sodium azide; pH 7.4 |
| Gene Alias | Keytruda |
| Host Species | Mouse |
| Immunogen | Pembrolizumab |
| Purification Method | Protein A |
| Show More |
By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.